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Purpose
Chamomile is a traditional herb known for its calming
effects. We are conducting a long-term, randomized,
placebo-substitution study of chamomile for the preven-
tion of recurrent Generalized Anxiety Disorder (GAD)
in individuals who have responded to initial, open-label
chamomile therapy. We present preliminary results
from the trial’s open label phase to offer initial evidence
of safety and effectiveness of chamomile in GAD.
Methods
A 38-week long-term relapse prevention trial with three
phases. I: Eight weeks to determine whether individuals
respond to chamomile; II: Four more weeks among
responders to determine whether symptoms remain stable;
III: An additional 26 weeks to determine whether chamo-
mile is superior to placebo in preventing the recurrence of
anxiety symptoms in responders. Subjects meet DSM IV-
TR criteria for GAD, moderate severity. Study interven-
tions include pharmaceutical grade chamomile extract
(SHR-5) 1,500 mg daily standardized to 1.2% apigenin and
comparable placebo. Primary outcome measures are the
GAD-7, Hamilton Anxiety Rating (HAM-A), and Clinical
Global Impression Severity (CGI/S) scales.
Results
To date, 63 subjects have been enrolled, median age 48,
range (24 to 71); 40 women, 23 men; 49 White, 6 African
American, 6 Asian, 2 Other. Among the 48 subjects who
completed phase I, a significant mean reduction of anxi-
ety symptoms, as measured by GAD-7 (13.4 to 5.4,
59.7%, p≤0.001) and HAM-A (16.3 to 5.5, 66.2%,
p≤0.001) have been observed. By a priori defined CGI-S
and by 50% symptom reduction in GAD-7, 38 of those
completing phase I (79.2%) met criteria for response. No
serious adverse events were observed.
Conclusion
Preliminary findings are consistent with our previous
RCT finding that over 50% of subjects with moderate or
severe GAD symptoms respond to chamomile. The
1500mg dose of chamomile oral extract appears to be
safe. More definitive and long-term relapse prevention
findings await the completion of the trial.
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